Riley Bove, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 19 years
- Harvard Medical School, 2007
Offices
1 location · UCSF Medical Group Business Services · 1,533 clinicians in this group
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bove’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A138800 · Current
Licensed to practise in California · since 2015 · expires 2027-10-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$4,848
Medicare paid this office $4,848 for 30 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 27 | $4,507 | $122 |
Who their Medicare patients are
30 Original Medicare patients in 2024. Average age 65 · 85 and older 0% · Health risk score 1.43. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 43%.
The office billed $30,782, Medicare allowed $6,406 and paid $4,848; for 49 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 30 | 49 | 65 | 1.43 | $30,782 | $4,848 |
| 2023 | 22 | 40 | 67 | 1.45 | $28,527 | $4,619 |
| 2022 | 28 | 47 | 62 | 1.50 | $31,546 | $5,063 |
| 2021 | 23 | 41 | 61 | 1.30 | $28,710 | $4,344 |
| 2020 | 25 | 30 | 63 | 1.29 | $20,408 | $2,654 |
| 2019 | 22 | 33 | 60 | 1.58 | $24,935 | $2,892 |
| 2018 | 21 | 33 | 58 | 1.44 | $23,944 | $3,120 |
| 2017 | 20 | 28 | 54 | 1.39 | $19,215 | $2,544 |
| 2016 | 13 | 16 | 56 | 1.31 | $12,222 | $1,794 |
| 2015 | 14 | 15 | 56 | 1.28 | $6,377 | $1,128 |
| 2014 | 17 | 23 | 57 | 0.88 | $8,734 | $2,047 |
| 2013 | 44 | 47 | 73 | 2.01 | $26,936 | $6,326 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Long return visit (40+ min) | 22 | $4,181 | $123 |
2022: 1 service
| Long return visit (40+ min) | 27 | $4,582 | $124 |
2021: 1 service
| Long return visit (40+ min) | 20 | $3,912 | $119 |
2020: 1 service
| Long return visit (40+ min) | 18 | $2,122 | $101 |
2019: 1 service
| Long return visit (40+ min) | 18 | $2,270 | $87 |
2018: 1 service
| Long return visit (40+ min) | 17 | $2,761 | $99 |
2017: 1 service
| Long return visit (40+ min) | 17 | $1,789 | $94 |
2015: 1 service
| Long return visit (40+ min) | 11 | $841 | $70 |
2014: 1 service
| Long return visit (40+ min) | 15 | $1,641 | $86 |
2013: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,561 | $163 |
Drugs they prescribed that Part D paid
$111,483
Pharmacies billed $111,483 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 141) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
131 generic and fewer than 11 brand-name prescriptions · $111,483 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dalfampridine Er | 15 | $6,152 | $410 |
| Teriflunomide | 20 | $2,240 | $112 |
| Gabapentin | 23 | $434 | $19 |
| Baclofen | 19 | $347 | $18 |
| Modafinil | 14 | $324 | $23 |
Year by year
| 2024 | 141 | 24 | 0% (0) | None | $111,483 |
| 2023 | 154 | 25 | 0% (0) | None | $191,115 |
| 2022 | 159 | 28 | 0% (0) | None | $324,974 |
| 2021 | 152 | 18 | 0% (0) | 27% | $312,129 |
| 2020 | 141 | 19 | 0% (0) | 29% | $341,384 |
| 2019 | 174 | 22 | 0% (0) | 36% | $357,464 |
| 2018 | 169 | 27 | 0% (0) | 41% | $381,784 |
| 2017 | 89 | 28 | None | 31% | $179,730 |
| 2016 | 23 | 12 | 0% (0) | 52% | $105,032 |
| 2015 | 142 | 14 | 0% (0) | 39% | $340,078 |
| 2014 | 132 | 20 | None | 39% | $267,700 |
| 2013 | 57 | 11 | None | 58% | $143,057 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Dalfampridine Er | 21 | $4,380 | $209 |
| Teriflunomide | 11 | $1,353 | $123 |
| Gabapentin | 27 | $949 | $35 |
| Baclofen | 25 | $701 | $28 |
2022: 3 drugs
| Aubagio | 21 | $171,097 | $8,147 |
| Baclofen | 24 | $1,296 | $54 |
| Gabapentin | 36 | $817 | $23 |
2021: 4 drugs
| Aubagio | 23 | $189,028 | $8,219 |
| Copaxone | 12 | $83,755 | $6,980 |
| Gabapentin | 37 | $742 | $20 |
| Baclofen | 19 | $707 | $37 |
2020: 3 drugs
| Aubagio | 12 | $108,570 | $9,048 |
| Copaxone | 12 | $82,541 | $6,878 |
| Gabapentin | 26 | $582 | $22 |
2019: 7 drugs
| Copaxone | 18 | $142,153 | $7,897 |
| Tecfidera | 14 | $110,741 | $7,910 |
| Aubagio | 11 | $77,386 | $7,035 |
| Modafinil | 11 | $2,633 | $239 |
| Cyclobenzaprine | 12 | $556 | $46 |
| Gabapentin | 18 | $296 | $16 |
| Amitriptyline | 11 | $261 | $24 |
2018: 3 drugs
| Copaxone | 15 | $115,683 | $7,712 |
| Ampyra | 27 | $91,397 | $3,385 |
| Clemastine | 13 | $1,730 | $133 |
2015: 6 drugs
| Aubagio | 17 | $98,399 | $5,788 |
| Betaseron | 11 | $59,831 | $5,439 |
| Mycophenolate Mofetil | 13 | $2,196 | $169 |
| Baclofen | 27 | $1,054 | $39 |
| Gabapentin | 18 | $836 | $46 |
| Lorazepam | 11 | $26 | $2 |
2014: 3 drugs
| Duloxetine | 12 | $3,870 | $323 |
| Gabapentin | 27 | $1,144 | $42 |
| Baclofen | 11 | $536 | $49 |
2013: 1 drug
| Copaxone | 11 | $51,913 | $4,719 |
Money from drug and device companies
$55,088 in 2025
| 2025 | 10 | 34 | $53,231 | $55,088 |
| 2024 | 8 | 42 | $57,990 | $62,406 |
| 2023 | 5 | 17 | $14,958 | $17,744 |
| 2022 | 10 | 23 | $21,708 | $23,547 |
| 2021 | 4 | 8 | $17,675 | $21,025 |
| 2020 | 7 | 11 | $29,443 | $29,443 |
| 2019 | 8 | 60 | $50,608 | $74,027 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| EMD Serono | None | $30,049 | 8 payments
|
| Genzyme | None | $8,567 | 3 payments
|
| TG Therapeutics | Briumvi | $7,248 | 14 payments
|
| Merck Healthcare KGaA | None | $3,780 | 1 payment
|
| Biogen | None | $2,740 | 1 payment
|
| Novartis Pharma AG | Kesimpta | $2,248 | 1 payment
|
See all 34 published payments
| Biogen | Consulting · 2025-11-17 | None | $2,740 |
| EMD Serono | Consulting · 2025-10-21 | None | $7,140 |
| Novartis Pharma AG | Consulting · 2025-10-21 | Kesimpta | $2,248 |
| Merck Healthcare KGaA | Paid to speak or teach · 2025-10-15 | None | $3,780 |
| TG Therapeutics | Consulting · 2025-09-30 | Briumvi | $2,700 |
| Genentech USA | Meals · 2025-09-25 | Ocrevus | $99 |
| TG Therapeutics | Meals · 2025-09-24 | Briumvi | $52 |
| TG Therapeutics | Meals · 2025-09-23 | Briumvi | $59 |
| TG Therapeutics | Meals · 2025-09-23 | Briumvi | $34 |
| TG Therapeutics | Meals · 2025-09-23 | Briumvi | $22 |
| Celgene | Meals · 2025-09-22 | None | $53 |
| Celgene | Meals · 2025-09-22 | None | $18 |
| TG Therapeutics | Meals · 2025-08-27 | Briumvi | $21 |
| TG Therapeutics | Consulting · 2025-08-22 | Briumvi | $338 |
| TG Therapeutics | Consulting · 2025-07-29 | Briumvi | $1,013 |
| Genzyme | Consulting · 2025-07-14 | None | $2,636 |
| EMD Serono | Meals · 2025-07-09 | None | $23 |
| EMD Serono | Consulting · 2025-06-16 | None | $10,080 |
| Genentech | Meals · 2025-05-30 | Ocrevus | $42 |
| Novartis Pharmaceuticals | Meals · 2025-05-29 | Kesimpta | $27 |
| Genentech USA | Meals · 2025-05-29 | Ocrevus | $217 |
| TG Therapeutics | Travel · 2025-04-25 | Briumvi | $527 |
| TG Therapeutics | Meals · 2025-04-25 | Briumvi | $105 |
| TG Therapeutics | Travel · 2025-04-25 | Briumvi | $316 |
| EMD Serono | Consulting · 2025-04-22 | None | $12,600 |
| TG Therapeutics | Meals · 2025-04-17 | Briumvi | $13 |
| EMD Serono | Meals · 2025-03-28 | None | $89 |
| EMD Serono | Meals · 2025-03-28 | None | $28 |
| EMD Serono | Meals · 2025-03-28 | None | $28 |
| EMD Serono | Meals · 2025-03-28 | None | $60 |
| Genzyme | Consulting · 2025-03-27 | None | $3,954 |
| Genzyme | Consulting · 2025-03-27 | None | $1,977 |
| TG Therapeutics | Consulting · 2025-02-28 | Briumvi | $2,025 |
| TG Therapeutics | Meals · 2025-02-26 | Briumvi | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $62,406
| Merck KGaA | Evobrutinib | $20,450 | 4 payments
|
| Alexion Pharmaceuticals | Soliris | $14,604 | 16 payments
|
| TG Therapeutics | Briumvi | $12,052 | 7 payments
|
| Amgen | Uplizna | $9,106 | 8 payments
|
| Genzyme | None | $5,787 | 2 payments
|
| Celgene | None | $233 | 2 payments
|
| EMD Serono | None | $150 | 2 payments
|
| Novartis Pharmaceuticals | Kesimpta | $25 | 1 payment
|
2023: $17,744
| TG Therapeutics | Briumvi | $9,248 | 10 payments
|
| F. Hoffmann-La Roche AG | None | $7,571 | 4 payments
|
| Horizon Therapeutics plc | Uplizna | $825 | 1 payment
|
| Genentech USA | Ocrevus | $66 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $35 | 1 payment
|
2022: $23,547
| Horizon Therapeutics plc | Uplizna | $10,372 | 10 payments
|
| Merck KGaA | None | $6,500 | 2 payments
|
| Biogen | Tysabri | $3,473 | 2 payments
|
| EMD Serono | None | $1,498 | 2 payments
|
| Janssen Global Services | Ponvory | $1,320 | 1 payment
|
| Novartis Pharmaceuticals | None | $116 | 1 payment
|
| TG Therapeutics | None | $110 | 2 payments
|
| Genentech USA | None | $108 | 1 payment
|
| Abbvie | Botox | $25 | 1 payment
|
| Genentech | Ocrevus | $25 | 1 payment
|
2021: $21,025
| Genzyme | Aubagio | $7,075 | 2 payments
|
| Merck KGaA | None | $5,500 | 1 payment
|
| Tg Therapeutics | None | $5,100 | 2 payments
|
| EMD Serono | None | $3,350 | 3 payments
|
2020: $29,443
| F. Hoffmann-La Roche AG | Ocrevus | $11,600 | 3 payments
|
| Genzyme | Aubagio | $8,625 | 3 payments
|
| EMD Serono | None | $3,000 | 1 payment
|
| Genentech USA | Ocrevus | $2,898 | 1 payment
|
| Janssen Research & Development | None | $2,000 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $1,020 | 1 payment
|
| Genentech | Ocrevus | $300 | 1 payment
|
2019: $74,027
| Novartis Pharma AG | Omb157g Arzerra Hematology | $17,374 | 8 payments
|
| Genzyme | Aubagio | $17,121 | 6 payments
|
| Genentech USA | Ocrevus | $16,027 | 14 payments
|
| F. Hoffmann-La Roche AG | Ocrevus | $6,974 | 8 payments
|
| EMD Serono | Rebif | $6,870 | 10 payments
|
| Alexion Pharmaceuticals | None | $5,220 | 9 payments
|
| Sanofi-Aventis U.S. | Aubagio | $3,524 | 3 payments
|
| Genentech | Ocrevus | $917 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| F. Hoffmann-La Roche AG · Digital Neurological Examination · 2024 | Their institution | $953,757 |
| F. Hoffmann-La Roche AG · Digital Neurological Examination · 2025 | Their institution | $635,838 |
| Genentech, Inc. · Menopause · 2023 | Their institution | $250,496 |
| Genentech, Inc. · Evaluating Pregnancy Outcomes in Minority Women With Ms · 2023 | Their institution | $246,147 |
| F. Hoffmann-La Roche AG · Digital Neurological Examination · 2022 | Their institution | $226,791 |
| Biogen, Inc. · US-Msg-18-11401 Houtchens Sra (Bove UCSF Site): Prospective Ascertainment (Aop 20-245 for 2020, Aop Line "New Up Iit / Sra: Data Generation & Publication" for 2021) · 2021 | Their institution | $138,311 |
| F. Hoffmann-La Roche AG · Intonate - Silent Progression Monitoring in Rr-Ms Patients. Sp-Ms Despite An Effective Early Highly Active Treatment As A Paradigm · 2025 | Their institution | $136,074 |
| Biogen, Inc. · Prospective Ascertainment of Peri-Childbirth Depression and Its Relationship With Postpartum Inflammatory Activity in Women With Ms · 2025 | Their institution | $127,672 |
| Genentech, Inc. · Breastmilk Assay · 2021 | Their institution | $107,952 |
| Hoffmann-La Roche Limited · Ocrelizumab Breast Milk Transfer Stud · 2025 | Their institution | $63,711 |
| Hoffmann-La Roche Limited · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2025 | Their institution | $58,054 |
| Hoffmann-La Roche Limited · Ocrelizumab Breast Milk Transfer Stud · 2022 | Their institution | $56,985 |
| Hoffmann-La Roche Limited · Ocrelizumab Placental Transfer Study · 2025 | Their institution | $52,694 |
| Genentech, Inc. · Breastmilk Assay · 2022 | Their institution | $49,406 |
| Hoffmann-La Roche Limited · Ocrelizumab Breast Milk Transfer Stud · 2023 | Their institution | $40,043 |
| Hoffmann-La Roche Limited · Ocrelizumab Placental Transfer Study · 2023 | Their institution | $36,265 |
| Novartis Pharmaceuticals Corporation · A Phase IV, Prsopective, Multicenter, Open-Label, Mother-Milk Study To Evaluate Ofatumumab Concentration in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis (Rms) Receving Kesimpta (Ofatumumab) · 2025 | Their institution | $32,967 |
| Novartis Pharmaceuticals Corporation · A Phase IV, Prsopective, Multicenter, Open-Label, Mother-Milk Study To Evaluate Ofatumumab Concentration in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis (Rms) Receving Kesimpta (Ofatumumab) · 2024 | Their institution | $28,216 |
| Hoffmann-La Roche Limited · Ocrelizumab Placental Transfer Study · 2024 | Their institution | $26,373 |
| Hoffmann-La Roche Limited · Ocrelizumab Placental Transfer Study · 2022 | Their institution | $21,843 |
| Lilly USA, LLC · 2025 | Their institution | $13,775 |
| Genentech, Inc. · Breastmilk Assay · 2023 | Their institution | $13,607 |
| Lilly USA, LLC · 2024 | Their institution | $7,500 |
| Hoffmann-La Roche Limited · Ocrelizumab Breast Milk Transfer Stud · 2024 | Their institution | $5,614 |
| F. Hoffmann-La Roche AG · An Open-Label, Single-Arm 4-Year Study To Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis · 2025 | This clinician | $4,526 |
| F. Hoffmann-La Roche AG · A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison To Interferon Beta-1a Rebif in Patients With Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison To Interferon Beta-1a Rebif in Patients With Relapsing Multiple Sclerosis, A Phase III, Multicentre, Randomized, Parallel-Group, Double Blinded, Placebo Controlled · 2020 | This clinician | $4,043 |
| Novartis Pharmaceuticals Corporation · Kesimpta Study Related Review Article Writing Support · 2023 | This clinician | $2,763 |
| F. Hoffmann-La Roche AG · Study of Ocrelizumab in Ppms Patients Assessing Upper Limb Function · 2025 | This clinician | $2,656 |
| F. Hoffmann-La Roche AG · A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison To Interferon Beta-1a Rebif in Patients With Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison To Interferon Beta-1a Rebif in Patients With Relapsing Multiple Sclerosis, A Phase III, Multicentre, Randomized, Parallel-Group, Double Blinded, Placebo Controlled S · 2021 | This clinician | $2,408 |
| F. Hoffmann-La Roche AG · Study of Ocrelizumab in Ppms Patients Assessing Upper Limb Function · 2023 | This clinician | $2,085 |
| F. Hoffmann-La Roche AG · Placental and Breastmilk Transfer of Ocrelizumab From Women With Multiple Sclerosis To Infants and the Potential Impact on B-Cell Levels: Primary Analysis of the Prospective, Multicenter, Open-Label, Phase IV Studies Minore and Sopranino · 2025 | This clinician | $2,003 |
| F. Hoffmann-La Roche AG · Ocrelizumab Placental Transfer Study · 2025 | This clinician | $1,599 |
| F. Hoffmann-La Roche AG · A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison To Interferon Beta-1a Rebif in Patients With Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison To Interferon Beta-1a Rebif in Patients With Relapsing Multiple Sclerosis, A Phase III, Multicentre, Randomized, Parallel-Group, Double Blinded, Placebo Controlled S · 2022 | This clinician | $1,496 |
| F. Hoffmann-La Roche AG · Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of Over 3000 Pregnancies To Date · 2024 | This clinician | $1,492 |
| F. Hoffmann-La Roche AG · Disease Activity Before, During and After Pregnancy in Women With Ms Receiving Ocrelizumab: An Integrated Analysis From 13 Interventional Clinical Trials · 2024 | This clinician | $1,488 |
| F. Hoffmann-La Roche AG · Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database · 2024 | This clinician | $1,295 |
| F. Hoffmann-La Roche AG · Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database · 2023 | This clinician | $1,285 |
| Biogen, Inc. · Study To Evaluate Oral Biib061 Added To Interferon-Beta1 (Ifn-1) in Relapsing Multiple Sclerosis (Rms) · 2019 | This clinician | $1,072 |
| Biogen, Inc. · Study To Evaluate Oral Biib061 Added To Interferon-Beta1 (Ifn-1) Or Glatiramer Acetate in Relapsing Multiple Sclerosis (Rms) · 2020 | This clinician | $1,050 |
| F. Hoffmann-La Roche AG · Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Receiving Ocrelizumab: Analysis of Approximately 4,000 Pregnancies To Date · 2024 | This clinician | $957 |
| F. Hoffmann-La Roche AG · Ocrelizumab Placental and Breastmilk Transfer From Women With Multiple Sclerosis To Infants · 2025 | This clinician | $861 |
| F. Hoffmann-La Roche AG · Disease Activity Before During and After Pregnancy in Women With Ms Receiving Ocrelizumab: An Integrated Analysis From 13 Interventional Clinical Trials · 2024 | This clinician | $842 |
| F. Hoffmann-La Roche AG · Ocrelizumab in Patients With Rms · 2024 | This clinician | $837 |
| Novartis Pharma AG · Comb157g23101 · 2021 | This clinician | $798 |
| F. Hoffmann-La Roche AG · B-Cell Levels and Breastmilk Transfer in Infants of Lactating Women With Multiple Sclerosis Treated With Ocrelizumab: Primary Results of the Prospective Multicentre, Open-Label Phase IV Study Sopranino · 2024 | This clinician | $670 |
| F. Hoffmann-La Roche AG · Primary Ms · 2023 | This clinician | $597 |
| F. Hoffmann-La Roche AG · Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Receiving Ocrelizumab: Analysis of Approximately 4000 Pregnancies To Date · 2024 | This clinician | $536 |
| F. Hoffmann-La Roche AG · B-Cell Levels, Humoral Responses and 1-Year Follow-Up in Infants Potentially Exposed To Ocrelizumab During Breastfeeding: the Prospective, Multicentre, Open-Label, Phase IV Sopranino Study · 2025 | This clinician | $477 |
| F. Hoffmann-La Roche AG · B-Cell Levels and Breastmilk Transfer in Infants of Lactating Women With Multiple Sclerosis Treated With Ocrelizumab: Primary Results of the Phase IV Study Sopranino · 2024 | This clinician | $469 |
| F. Hoffmann-La Roche AG · Placental and Breastmilk Transfer of Ocrelizumab From Women With Multiple Sclerosis To Infants and the Potential Impact on B-Cell Levels: Final Analysis of the Prospective, Multicentre, Open-Label, Phase IV Studies Minore and Sopranino · 2025 | This clinician | $449 |
| F. Hoffmann-La Roche AG · B-Cell Levels, Humoral Responses and 1-Year Follow-Up in Infants Potentially Exposed To Ocrelizumab During Pregnancy: the Prospective, Multicentre, Open-Label, Phase IV Minore Study · 2025 | This clinician | $449 |
| F. Hoffmann-La Roche AG · Floodlight Ms Moreactive · 2025 | This clinician | $380 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053516625
- Licence
- CA A138800, MA L-233102California A138800: Current · expires 2027-10-31
- Trained
- Harvard Medical School, 2007 · 19 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Neurology (2084N0400X)
- Mailing address
- 1500 Owens St Fl 3, San Francisco, CA, 94158
- NPI first listed
- 2007-06-15
- NPI last updated
- 2020-01-22
- NPI record certified
- 2020-01-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: Massachusetts General Hospital, Boston, MA, 02114